OncologyBristol Myers Squibb
Bristol Myers Squibb Reports Three-Year CheckMate-9ER Data for Opdivo Plus Cabometyx in RCC
BMI
Biotechnology Media Insights
Editorial Team · September 25, 2023
BMS presents three-year overall survival data from CheckMate-9ER trial showing durable benefit of Opdivo plus cabozantinib in advanced renal cell carcinoma.
Bristol Myers Squibb today presented three-year overall survival data from the Phase 3 CheckMate-9ER trial evaluating Opdivo (nivolumab) plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma. The data showed that the overall survival benefit of Opdivo plus cabozantinib was maintained at three years.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.